Placebo News and Research

RSS

ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO

ArQule, Inc. today announced that the following presentations of clinical data for ARQ 197, a selective inhibitor of the c-Met receptor tyrosine kinase, will take place at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held June 4-8, 2010 in Chicago, Illinois.

21 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, will present data from three Phase II clinical trials highlighting the clinical potential of its unique phosphatidylserine -targeting antibody bavituximab for the treatment of solid tumors.

21 May 2010

GFCF diet shows no significant benefits on the behavior of children with ASD: Study

A popular belief that specific dietary changes can improve the symptoms of children with autism was not supported by a tightly controlled University of Rochester study, which found that eliminating gluten and casein from the diets of children with autism had no impact on their behavior, sleep or bowel patterns.

20 May 2010

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

20 May 2010

Saint Louis University conducts research to find safe, effective vaccination for dengue

Sponsored by the National Institutes of Health, Saint Louis University's Center for Vaccine Development is conducting research of an investigational vaccine designed to prevent people from contracting dengue, a potentially lethal virus that has rapidly spread around the world.

20 May 2010

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Inspire Pharmaceuticals, Inc. announced today that Inspire scientists and collaborators will present data on denufosol tetrasodium, an investigational therapy for cystic fibrosis, during an oral presentation at the American Thoracic Society 2010 International Conference May 14 - 19, 2010 in New Orleans, LA.

20 May 2010

Daily ginger consumption reduces muscle pain caused by exercise: Researchers

For centuries, ginger root has been used as a folk remedy for a variety of ailments such as colds and upset stomachs. But now, researchers at the University of Georgia have found that daily ginger consumption also reduces muscle pain caused by exercise.

20 May 2010

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inviragen has announced the initiation of the first clinical trial of its vaccine to protect against dengue fever. The trial, to be conducted at Saint Louis University, is designed to assess the safety of Inviragen's investigational dengue vaccine.

20 May 2010

Gene therapy shows positive effects in rat models of PAH: Researchers

Gene therapy has been shown to have positive effects in rat models of pulmonary arterial hypertension, according to researchers at the University of Adelaide in Australia.

20 May 2010

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin

Significantly more pre-menopausal women with hypoactive sexual desire disorder (HSDD) reported a clinically meaningful improvement in their condition with flibanserin 100mg compared with placebo, according to new research announced today. Flibanserin is an investigational, non-hormonal treatment being developed by Boehringer Ingelheim for pre-menopausal women with HSDD.

19 May 2010

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Pearl Therapeutics Inc., a company developing clinically differentiated double and triple combination therapies for the treatment of highly prevalent chronic respiratory diseases, presented results from four studies that provide support for further development of PT003, the company's fixed dose combination of glycopyrrolate and formoterol delivered via a pressurized hydrofluoroalkane metered dose inhaler (HFA-MDI).

19 May 2010

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

This study formulates the hypothesis that rufinamide, a drug so far used against epilepsy, may also be effective in bipolar disorder, depressive and anxiety disorders, panic disorder and obsessive-compulsive disorder, eating disorders, and substance use disorders. It is just an hypothesis based on two cases that needs to be confirmed by specific studies.

19 May 2010

DanActive drink reduces rate of common sicknesses in daycare children, say researchers

The probiotic yogurt-like drink DanActive reduced the rate of common sicknesses such as ear infections, sinusitis, the flu and diarrhea in daycare children, say researchers who studied the drink in the largest known probiotic clinical trial to be conducted in the United States. An additional finding, however, showed no reduction in the number school days missed.

19 May 2010

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Data from pivotal Phase III clinical trials demonstrate that a higher proportion of pre-menopausal women with Hypoactive Sexual Desire Disorder (HSDD) receiving flibanserin 100mg reported both an improvement in their condition and a meaningful benefit from their treatment, compared to placebo.

19 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

The data from the initial clinical studies with KB001, a novel antibody fragment against PcrV on Pseudomonas aeruginosa (Pa) bioengineered by KaloBios Pharmaceuticals, Inc. and partnered with sanofi pasteur, demonstrated promising therapeutic activity in the prevention of serious lung infection in mechanically ventilated patients colonized with the bacterium and in limiting potentially damaging inflammation in patients with cystic fibrosis, where Pa plays an important role in the disease.

18 May 2010

Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes

Cerenis Therapeutics, a biopharmaceutical company focused on discovering and developing novel HDL therapies, today announced the completion of a Phase 1 study of the Company's CER-001 investigational product candidate to treat patients with acute coronary syndromes. Results of the completed study provide evidence that the investigational therapy was safe and well-tolerated at all dose levels evaluated, including those intended for future clinical development.

18 May 2010

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin™ (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans.

17 May 2010

Placebo News and Research

ArQule announces presentations on ARQ 197 c-Met inhibitor at 2010 ASCO

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Data from three Phase II clinical trials of PS-targeting antibody to be presented at 2010 ASCO Annual Meeting

GFCF diet shows no significant benefits on the behavior of children with ASD: Study

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Saint Louis University conducts research to find safe, effective vaccination for dengue

Scientists present data on denufosol tetrasodium for CF at ATS 2010 International Conference

Daily ginger consumption reduces muscle pain caused by exercise: Researchers

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Gene therapy shows positive effects in rat models of PAH: Researchers

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Pre-menopausal women with HSDD report clinically meaningful improvement with flibanserin

Pearl Therapeutics presents data supporting development of PT003 combination bronchodilator product

Studies suggest potent therapeutic effects of rufinamide in bipolar disorder, depressive and anxiety disorders

DanActive drink reduces rate of common sicknesses in daycare children, say researchers

Flibanserin benefits pre-menopausal women with Hypoactive Sexual Desire Disorder

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

KaloBios Pharmaceuticals' KB001 promising in prevention of serious lung infection

Cerenis' CER-001 Phase 1 study data supports continued clinical development for acute coronary syndromes

Mpex Pharmaceuticals presents Phase 2b trial results of Aeroquin for cystic fibrosis at ATS Annual Meeting

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News